While the company beat both EPS and revenue estimates with a significant 77.27% earnings surprise, the stock has significantly underperformed the market year-to-date (-18.3% vs S&P 500 +13.4%). The Zacks Rank #3 (Hold) rating and mixed estimate revisions suggest neutral near-term performance expectations despite the positive earnings beat.
AYTU BioPharma news
$2.20+1.38%
Close Sep 29, 2026 · split-adjustedArticles · 30 days2English, de-duplicated
Positive00% of coverage
Neutral2100%
Negative00% of coverage
About AYTU BioPharma
Zacks Investment ResearchSep 22, 5:15 PM ETNeutral
Also mentions AYTU
Articles that tag AYTU but are mainly about other companies.
Zacks Investment ResearchSep 14, 5:35 PM ETNeutral
Expected to report a quarterly loss of $0.22 per share with a year-over-year improvement of 15.4%. However, revenues are expected to decline 23.7% year-over-year, presenting mixed signals with no consensus estimate changes in the last 30 days.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology